Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page g1 V7 s7 I" X1 p X* [9 I
9 W8 D5 \- f7 ]' n) \- W/ g
& `. C; v' V: X! w* G, @Sub-category:
) E; ~ N; w! iMolecular Targets
3 Y6 w/ d0 ~/ @5 f+ Y4 A3 L. `' R. }8 C1 X# M3 x
( z* h0 G& k& Z0 g% I: s1 E- BCategory:
4 `& [2 c2 y5 LTumor Biology
; g0 Q. K. `/ e* e. ]! s( H5 C6 w' E2 ~- f
- E6 L/ A) \! z5 m
Meeting:
2 C+ G, V& k# L+ |/ N2011 ASCO Annual Meeting
# G: N9 c3 i. C0 p& e. U& O+ q L* k; o' j. Q
+ F- h& ^! p& P8 g
Session Type and Session Title:' q3 w, U# |' @9 ?4 d) d
Poster Discussion Session, Tumor Biology ! C$ W1 @8 ]: q/ N# e
5 m9 V" b: o* M: R
, p! T# T7 `4 a* |; T5 e" z
Abstract No:$ |5 ?' _) r/ o
10517 ; q& ~- |$ x# \1 [
8 r( e* `, i& j; |5 ~* _
' u6 e, d* w8 V* n' j: A2 W/ D2 R2 s oCitation:/ J8 `5 m( ^7 l) w2 ?
J Clin Oncol 29: 2011 (suppl; abstr 10517)
+ C; U( d) f4 ?# Z' z4 L# k3 r! i0 R/ L# M) S% _7 M7 z5 ^% ?% K
2 ]9 [9 h: _5 k$ U$ W0 R; E% I
Author(s): K) j$ I+ L6 y' V
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
* N& a" H5 Z5 r6 I1 g1 W' Y3 }
B8 G" o" ~; h$ P0 J& B: Z4 o! i2 b/ c( Z/ s% V" r0 i: O
# ?5 T( F: D+ X* n6 M& z, [# M9 p
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
0 }2 [* r; R' J" y6 j
7 [2 ~2 V, H: M3 S8 [$ c$ \* w% IAbstract Disclosures
$ h1 Q; B+ y6 c" I3 i+ Q6 i) x8 f- V* H' ~7 c8 ?4 p. n
Abstract:
" h3 k# d7 D/ Y! |8 ]
6 x: i5 |& W' T8 I7 }: K0 V
! u- ]7 t( x/ W1 w6 q- z; ZBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.7 N' h0 c- M! }+ h% y& u
u; I. D* x& L9 f" q' s' V4 \
1 o0 e( u! T% L |